Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TEN-010 |
| Trade Name | |
| Synonyms | RG-6146|JQ2|RO6870810|RG6146|RO-6870810 |
| Drug Descriptions |
RO6870810 (TEN-010) binds to the bromodomain of BET proteins preventing their interaction with acetylated histone peptides, thus disrupting chromatin remodeling, gene expression, and cell proliferation (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A49). |
| DrugClasses | BET Inhibitor (Pan) 33 |
| CAS Registry Number | 1349719-98-7 |
| NCIT ID | C112500 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + TEN-010 | Atezolizumab TEN-010 | 0 | 1 |
| Daratumumab + TEN-010 | Daratumumab TEN-010 | 0 | 1 |
| Rituximab + TEN-010 + Venetoclax | Rituximab TEN-010 Venetoclax | 0 | 1 |
| TEN-010 | TEN-010 | 0 | 3 |